Friday, September 18, 2020

Sans proper data Russian COVID-19 vaccine’s efficacy, safety unknown: CCMB Chief

Must Read

It’s a ‘Mirza-Malik reunion’ after seven months for Sania Mirza!

Hyderabad: Ace Tennis player Sania Mirza and baby Izhaan Mirza Malik finally flew to Dubai last week after seven...

Google Play store removes Paytm app citing gambling policy

New Delhi: Google has removed digital payments major Paytm’s app from its Play Store for allegedly violating its gambling policies. “Paytm...

Urmila thanks people for support after Kangana’s soft porn remark

Mumbai: Actor Urmila Matondkar on Friday expressed gratitude to the “real people of India” for supporting her after actor Kangana...

Hyderabad: The efficacy and safety levels of the vaccine developed by Russia for treating COVID-19 patients is not predictable in the absence of data, a top official of theCSIR-Centre for Cellular and Molecular Biology said on Wednesday.

His remarks come in the backdrop of Russian President Vladimir Putin’s announcement that his country has developed the world’s first vaccine against coronavirus.

Director of CCMB, Rakesh K Mishra said if people are “lucky” then the Russian vaccine will work.

“Both, efficacy and safety of the vaccine is still unknown. They haven’t conducted proper trials, whichis stage-III trials. That is when you get to know the efficacy, when it is tested on a large number of people and wait for two months and see whether they get a viral infection or not.

Doesn’t look like they have carried out (large scale testings) because if you have done it, then show us the data.

You cannot keep it confidential,” Mishra told PTI.

He noted that the vaccine ought to be carefully evaluated before it goes to people and any country or company not releasing the data with respect to vaccine was bad.

“It (Russian vaccine) is not safe.. normally in any country this should not be allowed unless the vaccine goes to stage 1, 2 and 3 trials.

I think the Russian government passed a law recently, a couple of months back, that they have to fast track the vaccine preparation,” the CCMB official said.

CCMB is India’s premier research organisation centre.

Asked about the progress of vaccines being developed by Indian pharmaceutical companies, Mishra said the data pertaining to Stage-I and II are yet to be published and it is expected that they may come by the end of August or first half of September.

“I will not be surprised if this first stage and second stage results are encouraging, because many vaccines have passed it. The real test is in stage-III,” he pointed out.

The first dose of the vaccine-Sputnik-V, developed by the Gamaleya National Research Center for Epidemiology and Microbiology of the Russian Healthcare Ministrywas administered to Putin’s daughter and she is stated to be ‘feeling well.’

Putin has claimed that the vaccine has proven efficient during tests, offering a lasting immunity from the coronavirus.

Subscribe us on The Siasat Daily - Google News

Latest News

It’s a ‘Mirza-Malik reunion’ after seven months for Sania Mirza!

Hyderabad: Ace Tennis player Sania Mirza and baby Izhaan Mirza Malik finally flew to...

Google Play store removes Paytm app citing gambling policy

New Delhi: Google has removed digital payments major Paytm’s app from its Play Store for allegedly violating its gambling policies. “Paytm Android app is temporarily unavailable...

Urmila thanks people for support after Kangana’s soft porn remark

Mumbai: Actor Urmila Matondkar on Friday expressed gratitude to the “real people of India” for supporting her after actor Kangana Ranaut called her a “soft...

Siddharth Suryanarayan’s comeback to Tollywood after 3 years

Hyderabad: South star Siddharth Suryanarayan’s last outing in the Telugu film industry was with the horror flick Gruham in 2017. It has been nearly...

Apple says happy Diwali with 1st India online store on Sep 23

New Delhi: Ending months of speculation, Apple is launching its first exclusive branded online store in India on September 23 just ahead of the...

More Articles Like This